A scientist from the University of Massachusetts Medical School recently found a way to improve photodynamic therapy, which basically makes use of specific light molecules to target cancer tumors. This is a relatively new discovery in the medical industry, but it is fast getting traction thanks to the multitude of potential applications.
Gang Han, Ph.D. is the one who designed the new way to take advantage of photodynamic therapy to improve upon it along with his team, Phys.org reports. Trained in biochemistry & molecular pharmacology, Han is an associate professor at the university.
He and his team explained how the carbazole-substituted BODIPY (Car-BDP) can vastly improve the results of photodynamic therapy thanks to its NIR absorption band. Since its singlet oxygen quantum yield is exceedingly high, it leads to some unique results.
"This study signals a major step forward in photodynamic therapy by developing a new class of NIR-absorbing biodegradable organic nanoparticles for a highly effective targeting and treatment of deep-tissue tumors," Han said.
The results of the study were posted on the Journal of the American Chemical Society, where Han explains that after using the PLA–PEG-FA, which is a highly biodegradable polymer to encapsulate Car-BDP, the compound formed nanoparticles that possessed small, uniformed, organic, and water-soluble properties and is able to target tumors.
This helps overcome one of the bigger challenges that stop the wider adoption of photodynamic therapy, which is how shallow the penetration to tissue is right now. Normally, this is addressed via the introduction of drugs that are non-toxic and sensitive to light. Once the drug is inside the body, a laser is tuned with the molecules of the substances in the drug, which then targets the tumor.
Han and his team are proposing to make the whole thing simpler using Car-BDP and pairing it with a lamp light that has low power density. The molecules released by this method can be tracked as well, which makes monitoring which tumors have been targeted much easier.


Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO
EU to Propose New Rules Limiting Children's Access to Social Media
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX
Trump Administration Launches AI Cybersecurity Partnership to Protect Critical Infrastructure
RFK Jr. Orders Extended Hantavirus Quarantine for Cruise Passenger
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand
US Plans Kenya Ebola Quarantine Facility Amid Congo Outbreak
Trump Reportedly Approves Plan to Remove FDA Commissioner Marty Makary Amid Growing Controversies 



